Product Description
AR-701 is being developed by Aridis for the treatment and prevention of COVID-19. (Sourced from: https://www.aridispharma.com/ar-701/)
Mechanisms of Action: S2 Coronavirus Stalk Region Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aridis
Company Location: LOS GATOS CA 95032
Company CEO: Vu Truong
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|